Skip to content
drillr.ai
Sign up

REGN

Regeneron Pharmaceuticals, Inc.

NASDAQ · Healthcare · Biotechnology · US

$827.72
−1.87%
Ask drillr

  • Sep 1, 2026, 19:53 UTC

    The Portnoy Law Firm announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who bought securities between August 1, 2025 and May 15, 2026, alleging false statements during the Class Period.

    Source:

  • Aug 22, 2026, 07:10 UTC

    Allworth Financial LP acquired a new position of 2,530 shares in Regeneron Pharmaceuticals, Inc. during the second quarter, as disclosed in its 13F filing.

    Source:

  • Aug 21, 2026, 08:39 UTC

    A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. alleging violations of securities laws, and investors are being notified of their rights to seek lead plaintiff appointment.

    Source:

  • Aug 19, 2026, 17:02 UTC

    Regeneron Pharmaceuticals' drug Pasatru for fibrodysplasia ossificans progressiva (FOP) won regulatory approval on Wednesday, August 19, 2026.

    Source:

  • Aug 18, 2026, 07:55 UTC

    BlackRock Inc. acquired a new position in Regeneron Pharmaceuticals, Inc. during the second quarter, purchasing 9,113,506 shares valued at approximately $5.68 billion, according to its 13F filing.

    Source:

  • Aug 17, 2026, 09:05 UTC

    Focus Partners Advisor Solutions LLC acquired a new position in Regeneron Pharmaceuticals, Inc., purchasing 2,165 shares valued at approximately $1.35 million, as disclosed in a 13F filing.

    Source:

  • Aug 17, 2026, 08:19 UTC

    AMG National Trust Bank established a new position in Regeneron Pharmaceuticals, Inc. by purchasing 1,956 shares valued at approximately $1.22 million during the second quarter, as disclosed in its 13F filing.

    Source:

  • Aug 13, 2026, 00:00 UTC

    Parabilis Medicines, Inc. entered into a collaboration with Regeneron, receiving $50 million upfront and a $75 million equity investment, with potential milestone payments of up to $2.2 billion.

  • Aug 12, 2026, 14:09 UTC

    A securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026, alleging control-person liability related to public clinical-trial statements and SEC disclosures.

    Source:

  • Aug 11, 2026, 11:24 UTC

    Zoomex launched twelve new USDT-margined stock perpetual contracts for UnitedHealth Group, General Electric, JPMorgan Chase, Gilead Sciences, Regeneron Pharmaceuticals, Amgen, Walmart, Coca-Cola, PepsiCo, Mastercard, PayPal Holdings, and Berkshire Hathaway Class B, offering 24/7 long and short trading with up to 25x leverage.

    Source:

  • Aug 3, 2026, 11:05 UTC

    Biocon announced the U.S. commercial launch of Yesafili, a biosimilar to Regeneron's Eylea 2 mg, for treating various ophthalmology conditions.

    Source:

  • Aug 1, 2026, 07:47 UTC

    Bank of America Corp DE increased its stake in Regeneron Pharmaceuticals, Inc. by 2.8% during the quarter, acquiring 32,158 additional shares, according to its 13F filing.

    Source:

  • Jul 30, 2026, 10:56 UTC

    Regeneron Pharmaceuticals reported its Q2 FY2026 financial results, with revenue up 16.7% to $4.2907 billion and operating profit up 19.8% to $1.2935 billion.

    Source:

  • Jul 24, 2026, 10:36 UTC

    A class action lawsuit was filed against Regeneron Pharmaceuticals and certain senior executives for securities fraud related to misrepresentations about its clinical trials.

    Source:

  • Jun 29, 2026, 18:53 UTC

    The FDA selected Eli Lilly and Regeneron among the first seven companies for its PreCheck Pilot Program to speed review of new manufacturing facilities.

    Source:

  • Jun 23, 2026, 19:26 UTC

    Regeneron's applications for cemdisiran in generalized myasthenia gravis were accepted by the FDA and EMA, with FDA granting Priority Review.

    Source:

  • Jun 11, 2026, 00:00 UTC

    Parabilis Medicines, Inc. signed a private placement of 4,166,666 shares of voting common stock at $18.00 per share, raising $75,000,000 from Regeneron Pharmaceuticals, Inc., concurrent with its initial public offering.

  • Jun 4, 2026, 18:25 UTC

    Regeneron expands its partnership with CytomX to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.

    Source:

  • Jun 3, 2026, 00:00 UTC

    CytomX Therapeutics amended its collaboration and license agreement with Regeneron Pharmaceuticals, extending Regeneron's program selection period and allowing up to eight new collaboration programs, with Regeneron nominating the first two programs and CytomX receiving $37.0 million in aggregate target nomination payments.

    Source:

  • Jun 1, 2026, 15:35 UTC

    Regeneron Pharmaceuticals reported first-quarter earnings that exceeded analyst estimates, driven by strong sales of Dupixent and Eylea HD.

    Source: